What if a cheap daily oral GLP-1 pill collapses branded drug pricing?
Trade the relative, not the index: a sub-$50 oral GLP-1 collapses branded pen/pill pricing — short Novo/Lilly and pen-device suppliers, long payers/PBMs and GLP-1-sensitive staples that re-rate on cheaper access. Rhymes with Sovaldi/Harvoni's Hep-C price collapse that gutted Gilead's franchise value. It is a disinflationary, intra-sector rotation — the tiny +growth_surprise risk-on cascade is immaterial and roughly the wrong frame, but harmless at this scale.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. A sub-$50 once-daily generic-priced oral GLP-1 wins FDA approval, collapsing branded pill and injectable-pen pricing and gutting device-supplier margins. The trigger decomposes into signed root‑shocks — Growth surprise ▲ — which propagate through our causal graph to the markets below.